A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy

Basal cell carcinoma (BCC) is the most frequent cancer in humans and results from constitutive activation of the Hedgehog pathway 1 . Several Smoothened inhibitors are used to treat Hedgehog-mediated malignancies, including BCC and medulloblastoma 2 . Vismodegib, a Smoothened inhibitor, leads to BCC shrinkage in the majority of patients with BCC 3 , but the mechanism by which it mediates BCC regression is unknown. Here we used two genetically engineered mouse models of BCC 4 to investigate the mechanisms by which inhibition of Smoothened mediates tumour regression. We found that vismodegib mediates BCC regression by inhibiting a hair follicle-like fate and promoting the differentiation of tumour cells. However, a small population of tumour cells persists and is responsible for tumour relapse following treatment discontinuation, mimicking the situation found in humans 5 . In both mouse and human BCC, this persisting, slow-cycling tumour population expresses LGR5 and is characterized by active Wnt signalling. Combining Lgr5 lineage ablation or inhibition of Wnt signalling with vismodegib treatment leads to eradication of BCC. Our results show that vismodegib induces tumour regression by promoting tumour differentiation, and demonstrates that the synergy between Wnt and Smoothened inhibitors is a clinically relevant strategy for overcoming tumour relapse in BCC.